Literature DB >> 34001945

Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.

Ismael Artur da Costa-Rocha1, Ketty Lysie Libardi Lira Machado2, Ana Carolina Campi-Azevedo1, Andréa Teixeira-Carvalho1, Vanessa Peruhype-Magalhães1, Sheila Maria Barbosa de Lima3, Emily Hime Miranda3, Gisela Freitas Trindade3, Thays Zanon Casagrande2, Samira Tatiyama Miyamoto2, Sávio Carvalho Deotti2, Rafaela Villa Real Barbosa2, Priscila Costa Martins Rocha2, Erica Vieira Serrano2, Valquiria Garcia Dinis2,4, Sônia Alves Gouvêa2, Maria Bernadete Renoldi de Oliveira Gavi2, Lidia Balarini da Silva2, Ruben Horst Duque2, Ana Paula Espíndula Gianordoli2, Maria de Fatima Bissoli2, Maria da Penha Gomes Gouvea2, Lauro Ferreira da Silva Pinto-Neto4, Ana Paula Neves Burian5, Francieli Fontana Sutile Tardetti Fantinato6, Gecilmara Salviato Pileggi7, Licia Maria Henrique da Mota8, Valéria Valim9, Olindo Assis Martins-Filho10.   

Abstract

The present study aimed to investigate whether the serum biomarkers of immune response orchestrate the seroconversion status in patients with autoimmune diseases (AID) upon planned primary 17DD-YF vaccination. For this purpose a total of 161 individuals were enrolled in a prospective study, including patients with Rheumatoid Arthritis (RA = 38), Spondyloarthritis (SpA = 51), Systemic Lupus Erythematosus (SLE = 21) and Sjögren's Syndrome (SS = 30) along with a group of healthy controls (HC = 21). Analysis of plaque reduction neutralization test (PRNT) titers and seropositivity rates along with the 17DD-YF viremia and serum biomarkers were carried out at distinct time points (D0/D3-4/D5-6/D7/D14-28). The results demonstrated an overall lower PRNT titer and seropositivity rate (170 vs. 448; 77 vs. 95%) in AID as compared to HC, especially in SpA and SLE subgroups. No significant differences were observed in the viremia levels amongst groups. In general, a more prominent serum biomarker response was observed in AID as compared to HC, throughout the timeline kinetics. Remarkably, AID/PRNT(-) exhibited higher levels of several biomarkers at baseline as compared to AID/PRNT+. Moreover, while AID/PRNT(+) exhibited earlier increase in serum biomarkers at D3-4/D5-6, the AID/PRNT(-) displayed higher response at later time points (D7/D14-D28). Of note, a synchronic increase of IFN-γ at the peak of viremia (D5-6) was observed in HC and AID/PRNT(+) groups, whereas a later asynchronous IFN-γ response was reported for AID/PRNT(-) at D7. The biomarker profile tends to deflate at post-vaccination timeline, highlighting a putative immunomodulatory effect of live attenuated 17DD-YF vaccine in AID/PRNT(+), but not in AID/PRNT(-). Altogether these data suggested that inflammatory status prior vaccination, low IFN-γ at viremia peak and the occurrence of asynchronous biomarker storm after 17DD-YF vaccination may orchestrate the lack of neutralizing antibody response γ.

Entities:  

Year:  2021        PMID: 34001945     DOI: 10.1038/s41598-021-89770-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  26 in total

Review 1.  Yellow fever.

Authors:  Thomas P Monath; Pedro F C Vasconcelos
Journal:  J Clin Virol       Date:  2014-10-24       Impact factor: 3.168

2.  Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.

Authors:  Ana C V Oliveira; Licia M H Mota; Leopoldo L Santos-Neto; Marisol Simões; Olindo A Martins-Filho; Pedro L Tauil
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

3.  17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.

Authors:  R W Wieten; A Goorhuis; E F F Jonker; G J de Bree; A W de Visser; P J J van Genderen; E B M Remmerswaal; I J M Ten Berge; L G Visser; M P Grobusch; E M M van Leeuwen
Journal:  J Infect       Date:  2016-03-24       Impact factor: 6.072

Review 4.  Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day.

Authors:  Natalie D Collins; Alan D T Barrett
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

Review 5.  Review of the risks and benefits of yellow fever vaccination including some new analyses.

Authors:  Thomas P Monath
Journal:  Expert Rev Vaccines       Date:  2012-04       Impact factor: 5.217

Review 6.  Treatment of yellow fever.

Authors:  Thomas P Monath
Journal:  Antiviral Res       Date:  2007-11-20       Impact factor: 5.970

Review 7.  Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.

Authors:  Florian Douam; Alexander Ploss
Journal:  Trends Microbiol       Date:  2018-06-19       Impact factor: 17.079

8.  Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication.

Authors:  Rosanne W Wieten; Emile F F Jonker; Daan K J Pieren; Caspar J Hodiamont; Pieter P A M van Thiel; Eric C M van Gorp; Adriëtte W de Visser; Martin P Grobusch; Leo G Visser; Abraham Goorhuis
Journal:  Vaccine       Date:  2016-02-01       Impact factor: 3.641

9.  Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Authors:  Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-09

10.  A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination.

Authors:  Rosanne W Wieten; Emile F F Jonker; Ester M M van Leeuwen; Ester B M Remmerswaal; Ineke J M Ten Berge; Adriëtte W de Visser; Perry J J van Genderen; Abraham Goorhuis; Leo G Visser; Martin P Grobusch; Godelieve J de Bree
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.